{
    "nctId": "NCT00005879",
    "briefTitle": "LY353381 in Preventing Breast Cancer in Women With Hyperplasia",
    "officialTitle": "A Phase II Clinical Trial of a Selective Estrogen Receptor Modulator (LY353381*HCl) in High Risk Women With Fine Needle Aspiration Cytologic Evidence of Hyperplasia",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 199,
    "primaryOutcomeMeasure": "Change in Masood Score",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Current random fine needle breast aspiration (FNA) evidence of 1 of the following:\n\n  * Hyperplasia with atypia\n  * Hyperplasia without atypia but with a 10-year modified Gail risk of at least 4%\n  * Hyperplasia without atypia but with a BRCAPRO risk of at least 25%\n  * Hyperplasia without atypia but with a known mutation in BRCA1 or BRCA2\n  * Hyperplasia without atypia but with a history of contralateral ductal carcinoma in situ or invasive breast cancer\n* FNA must have been taken during days 1-14 of the menstrual cycle for premenopausal women\n* Classified as ACR class I-III on mammogram with stepwedge within past 6 months If intact uterus and/or ovaries, must have color doppler transvaginal pelvic sonogram within past 6 months showing endometrial thickening no greater than 13 mm premenopausal or no greater than 8 mm postmenopausal\n\n  * No ovarian cysts felt to be possibly or probably non-physiologic that have not resolved to gynecologist's satisfaction on repeat sonogram\n* Must agree to have or have had genetic counseling and genetic testing performed for BRCA1 and BRCA2\n* No active cancer (e.g., detectable disease)\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 18 and over\n\nSex:\n\n* Female\n\nMenopausal status:\n\n* Any\n\nPerformance status:\n\n* Not specified\n\nLife expectancy:\n\n* At least 12 months\n\nHematopoietic:\n\n* Hemoglobin greater than 10 g/dL\n* Granulocyte count greater than 1,000/mm\\^3\n* No deficiencies in protein C, protein S, or antithrombin III\n* No activated protein C resistance\n\nHepatic:\n\n* Albumin greater than 3.0 g/dL\n* Bilirubin less than 1.5 mg/dL\n* AST less than 100 U/L\n* Alkaline phosphatase less than 200 U/L\n\nRenal:\n\n* Creatinine less than 1.5 mg/dL\n\nCardiovascular:\n\n* No history of deep venous thrombosis not related to trauma or pregnancy\n* No severe coronary artery disease\n* No history of prior stroke\n\nOther:\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 3 months after study\n* No other active cancer\n* No retinal vein thrombosis\n* No concurrent severe poorly controlled migraine\n* No factor V Leiden mutation carrier\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* At least 12 months since prior immunotherapy\n\nChemotherapy:\n\n* At least 3 months between completion of prior KUMC phase II difluoromethylornithine (DFMO) study and baseline aspiration\n* At least 12 months since prior chemotherapy\n\nEndocrine therapy:\n\n* Must not have started or stopped hormone replacement therapy or oral contraceptives within 6 months of baseline aspiration\n* Must continue all hormone replacement therapy and/or oral contraceptives that were being taken at time of baseline aspiration\n* At least 12 months since prior tamoxifen, raloxifene, or other antihormonal therapy\n\nRadiotherapy:\n\n* At least 3 months since prior radiotherapy\n\nSurgery:\n\n* At least 6 months between prior oophorectomy and baseline aspiration\n\nOther:\n\n* At least 2 weeks since the start of other new medication that would be ingested for 1 or more months",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}